Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor α and melphalan without massive tumor necrosis: A clinical and histopathological study of the delayed-type reaction pattern

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4880-4887

  Nooijen, Peet T G A ^a   Eggermont, Alexander M M ^b   Schalkwijk, Lia ^a   Henzen Logmans, Sonja ^b   De Waal, Robert M W ^a   Ruiter, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REGIONAL PERFUSION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR BIOPSY; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NECROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032211275     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Eggermont, A. M. M. Treatment of melanoma-in-transit metastases confined to the limb. Cancer Surv., 26: 335-349, 1996.
2. Liénard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High doses of rTNF-α in combination with IFN-γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
3. Lejeune, F. J., Liénard, D., Eggermont, A. M. M., Schraffordt Koops, H., Rosenkaimer, F., Gerain, J., Klaase, J., Kroon, B. B. R., Vanderveken, J., and Schmitz, P. Rationale for using TNF-α and chemotherapy in regional therapy of melanoma. J. Cell. Bioehem., 56: 62-61, 1994.
4. Liénard, D., Eggermont, A. M. M., Schraffordt Koops, H., Kroon, B. B. R., Rosenkaimer, F., Autier, P., and Lejeune, F. J. Isolated limb perfusion of the limb with high dose TNF-α and melphalan for melanoma stage III: results of a multicenter pilot study. Melanoma Res., 4: 21-26, 1994.
5. Eggermont, A. M. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B. R., van Geel, A. N., Hoekstra, H. J., and Lejeune, F. J. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol., 14: 2653-2665, 1996.
6. Eggermont, A. M. M., Schraffordt Koops, H., Klausner, J. M., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., Kettelhack, C., Ben Ari, G., Pector, J. C., and Lejeune, F. J. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg., 224: 756-765, 1996.
7. Renard, N., Liénard, D., Lespagnard, L., Eggermont, A. M. M., Heimann, R., and Lejeune, F. J. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor α (rTNF-α). Int. J. Cancer, 57: 656-663, 1994.
8. Krosnick, J. A., Mule, J. J., McIntosh, J. K., and Rosenberg, S. A. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res., 49: 3729-3733, 1989.
9. Manda, T., Shimomura, K., Mukumoto, S., Kobayashi, K., Mizota, T., Hirai, O., Matsumoto, S., Oku, T., Nishigaki, F., Mon, J., and Kikuchi, H. Recombinant human tumor-necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res., 47: 3707-3711, 1987.
10. Nawroth, P., Handley, D., Matsueda, G., De Waal, R. M. W., Gerlach, H., Blohm, D., and Stem, D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med., 168: 637-647, 1988.
11. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset Publ. No. 48., Geneva: WHO, 1979.
12. Kroon, B. B. R. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur. J. Surg. Oncol., 14: 101-110, 1988.
13. Renard, N., Nooijen, P. T. G. A., Schalkwijk, L., De Waal, R. M. W., Eggermont, A. M. M., Liénard, D., Kroon, B. B. R., Lejeune, F. J., and Ruiter, D. J. VWF release and platelet aggregation in human melanoma after perfusion with TNF-α. J. Pathol., 776: 279-287, 1995.
14. Carswell, E. A., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Nat. Acad. Sci. USA, 72: 3666-3370, 1975.
15. Palladino, M. A., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., et al. Characterization of the anti-tumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 138: 4023-4032, 1987.
16. de Kossodo, S., Moore, R., Gschmeissner, S., East, N., Upton, C., and Balkwill, F. R. Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumor necrosis. Br. J. Cancer, 72: 1165-1172, 1995.
17. Nooijen, P. T. G. A., Eggermont, A. M. M., Verbeek, M. M., Schalkwijk, L., Buurman, W. A., de Waal, R. M. W., and Ruiter, D. J. Transient induction of E-selectin expression following TNF-α-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J. Immunother., 19: 33-44, 1996.
18. Mulé, J. J., Asher, A., McIntosh, J., Lafreniere, R., Shiloni, E., Lefor, A., Reichert, C. M., and Rosenberg, S. A. Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol. Immunother., 26: 202-208, 1988.
19. Fraker, D. L. What is the best regional therapy? Melanoma Res., 7 (Suppl. 1): S42, 1997.
20. Blum, S., Liénard, D., Cerottini, J. C., et al. Phenotype changes occurring in peripheral blood T lymphocytes from patients treated by high dose rTNF-α in isolated limb perfusion. Eur. Cytokine Netw., 5: 235, 1994.
21. Blessing, K., and McLaren, K. M. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology (Oxf.), 20: 315-322, 1992.
22. Nathanson, L. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features and possible mechanisms. J. Natl. Cancer Inst. Monogr., 44: 67-76, 1976.
23. Ralfkiaer, E., Hou-Jensen, K., Gatter. K. C., Drzewiecki, K. T., and Mason, D. Y. Immunohistochemical analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. A Pathol. Anat. Hist., 410: 355-361, 1987.
24. Kernohan, N. M., Sewell, H. F., and Walker, F. Natural killer cells in cutaneous malignant melanoma. J. Pathol., 161: 35-40, 1990.
25. Szekers, L., and Orfanos, C. E. Alterations of the clinically noninvolved skin in patients with malignant melanoma. Dermatologica (Basel), 156: 142-154, 1978.
26. Hashimoto, K., and Ohyama, H. Cross-banded filamentous aggregation in the human dermis. J. Invest. Dermatol., 62: 106-112, 1974.
27. Runne, U., and Orfanos, C. E. Amyloid production by dermal fibroblasts. Br. J. Dermatol., 97: 155-166, 1977.
28. Oxenhandler, R. W., Berkelhammer, J., Smith, G. D., and Hook R. R., Jr. Growth and regression of cutaneous melanomas in Sinclair miniature swine. Am. J. Pathol., 109: 259-269, 1982.
29. Greene, J. F., Townsend, T. S., Jr., and Amoss, M. S. Histopathology of regression in Sinclair swine model of melanoma. Lab. Invest., 71: 17-24, 1994.
30. Mantovani, A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab. Invest., 71: 5-16, 1994.
31. Graves, D. T., Barnhill, R., Galanopoulos, T., and Antoniades, H. N. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am. J. Pathol., 140: 9-14, 1992.
32. Nissen Meyer, J., and Espevik, T. Effect of antisera against recombinant tumor necrosis factor and the monocyte-derived cytotoxin(s) on monocyte mediated killing of various tumor cells. Cell. Immunol., 109: 384-396, 1987.
33. Rios, A., Hersh, E. M., Gutterman, J. U., Mavligit, G. M., Schimek, H., McEntire. J. E., and Papermaster, B. W. The use of leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. Cancer (Phila.), 44: 1615-1621, 1979.
34. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G. Co-expression of B7-1 and ICAM-In tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol., 25: 1154-1162, 1995.
35. Abdel-Wahab, Z., Li, W. P., and Osanto, S. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell. Immunol., 159: 26-39, 1994.
36. Rodgers, S., Rees, R. C., and Hancock, B. W. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br. J. Haematol., 86: 746-753, 1994.
37. Manusama, E. R., Nooijen, P. T. G. A., Stavast, J., Durante, N. M., Marquet, R. L., and Eggermont, A. M. M. Synergistic anti-tumor effect of recombinant human tumor necrosis factor α (TNF-α) with melphalan in isolated limb perfusion in the rat. Br. J. Surg., 83: 551-555, 1996.
38. Nooijen, P. T. G. A., Manusama, E. R., Eggermont, A. M. M., Schalkwijk, L., Stavast, J., Marquet, R. L., De Waal, R. M. W., and Ruiter, D. J. Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma; a histopathological, immunohistochemical and electron microscopical study. Br. J. Cancer, 74: 1908-1915, 1996.
39. Partridge, C. A., Horvath, C. J., Del Vecchio, P. J., Phillips, P. G., and Malik, A. B. Influence of extracellular matrix in tumor-necrosis factor-induced increase in endothelial permeability. Am. J. Physiol., 263: L629-L633, 1992.
40. Vargas, H. I., Mc Farlane, M., Vargas, M. P., Seidel, J., Green, M., Alexander, H. R., and Fraker, D. L. Effects of tumor necrosis factor on vascular permeability and blood flow in tumor and normal tissue. Proc. Am. Assoc. Cancer Res., 37: 486, 1996.
41. Kristensen, C. A., Nozue, M., Boucher, Y., and Jain, R. K. Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br. J. Cancer, 74: 533-536, 1996.
42. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
43. Manjo, G., and Joris, J. Apoptosis, oncosis, and necrosis: an overview of cell death. Am. J. Pathol., 146: 3-15, 1995.